Anzeige
Mehr »
Dienstag, 02.06.2026 - Börsentäglich über 12.000 News
Entsteht hier die nächste Quantum-Story?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QA7 | ISIN: US80880X1046 | Ticker-Symbol: 4E4
Tradegate
28.05.26 | 07:50
0,345 Euro
+1,47 % +0,005
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SCIENTURE HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
SCIENTURE HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3270,34916:36

Aktuelle News zur SCIENTURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:06Scienture Holdings, Inc.: SCIENTURE Receives U.S. Patent Covering REZENOPY (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 204141U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing...
► Artikel lesen
FrScienture Holdings, Inc. - 8-K, Current Report10
22.05.Scienture Holdings, Inc. - 8-K, Current Report1
18.05.Scienture Holdings, Inc.: SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion262COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing...
► Artikel lesen
SCIENTURE Aktie jetzt für 0€ handeln
07.05.Scienture sichert sich Fremdfinanzierung über 11 Mio. US-Dollar für Produkteinführungen1
07.05.Scienture sichert sich 11 Millionen US-Dollar durch nicht-verwässernde Fremdfinanzierung2
07.05.Scienture Holdings, Inc.: Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline671Proceeds support commercialization of Arbli, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY, life-saving opioid overdose emergency treatment Financing also drives...
► Artikel lesen
06.05.Scienture Holdings, Inc.: SCIENTURE Announces Third Patent Grant for ARBLI (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041359U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI as the first FDA-approved ready-to-use oral suspension COMMACK...
► Artikel lesen
01.05.Scienture Holdings, Inc. - 8-K, Current Report-
30.04.Scienture Holdings, Inc. - 10-K/A, Annual Report-
15.04.NASDAQ gewährt Scienture Fristverlängerung zur Erfüllung der Mindestkursanforderung1
15.04.Scienture receives Nasdaq extension to regain compliance1
15.04.Scienture Holdings, Inc.: Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement634COMMACK, NY, April 15, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing...
► Artikel lesen
15.04.Scienture granted 180-day extension by Nasdaq to regain compliance2
06.04.Scienture posts 216% revenue growth, plans second product launch1
06.04.Scienture Holdings, Inc.: Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead220COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing...
► Artikel lesen
30.03.Scienture Holdings, Inc. GAAP EPS of -$2.70, revenue of $0.43M4
30.03.Scienture reports 216% revenue growth, gross margin expansion9
30.03.Scienture Holdings, Inc.: SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update236Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing...
► Artikel lesen
30.03.EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 20258
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1